Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)

Dr. Franck F. Rahaghi

Pulmonary Medicine | Intensive Care Medicine
Cleveland Clinic Florida (A Nonprofit Corporation)
2950 Cleveland Clinic Blvd, 
Weston, FL 
 (304.0 mi)
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)
Cleveland Clinic Florida (A Nonprofit Corporation)
2950 Cleveland Clinic Blvd, 
Weston, FL 
 (304.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Franck Rahaghi is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Weston, Florida. MD. Rahaghi and is rated as a Distinguished provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency (AATD), Interstitial Lung Disease, Lung Transplant, and Vertebroplasty. MD. Rahaghi is currently accepting new patients.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Alpha-1 Antitrypsin Deficiency (AATD).

Specialties
Pulmonary Medicine
Intensive Care Medicine
Licenses
Internal Medicine in FL
Hospital Affiliations
Cleveland Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Health Options
  •  Humana
  •  Florida Blue

Locations

CLEVELAND CLINIC FLORIDA (A NONPROFIT CORPORATION)
2950 Cleveland Clinic Blvd, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Recruiting
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Completed
Publish Date: February 05, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
A Phase 3/4 Study to Evaluate the Safety, Immunogenicity, and Effects on the Alpha1-Proteinase Inhibitor (A1PI) Levels in Epithelial Lining Fluid Following Glassia Therapy in A1PI-Deficient Subjects
Enrollment Status: Completed
Publish Date: October 14, 2021
Intervention Type: Biological
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 8 Less Clinical Trials

43 Total Publications

A 76-Year-Old-Man With Dyspnea and Abnormal Oximetry Run.
A 76-Year-Old-Man With Dyspnea and Abnormal Oximetry Run.
Journal: Chest
Published: March 28, 2024
Similar Doctors
Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Nydia P. Martinez-Galvis
Pulmonary Medicine | Intensive Care Medicine
Distinguished in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Nydia P. Martinez-Galvis
Pulmonary Medicine | Intensive Care Medicine

Cleveland Clinic Florida (A Nonprofit Corporation)

2950 Cleveland Clinic Blvd, 
Weston, FL 
954-659-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nydia Martinez-Galvis is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Weston, Florida. Dr. Martinez-Galvis and is rated as a Distinguished provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). Her top areas of expertise are Lung Metastases, Interstitial Lung Disease, Alpha-1 Antitrypsin Deficiency (AATD), and Acute Interstitial Pneumonia. Dr. Martinez-Galvis is currently accepting new patients.

Advanced in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Michael A. Campos
Intensive Care Medicine | Pulmonary Medicine
Advanced in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Michael A. Campos
Intensive Care Medicine | Pulmonary Medicine

University Of Miami

1400 Nw 12th Ave, 
Miami, FL 
 (22.2 mi)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Campos is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Miami, Florida. Dr. Campos and is rated as an Advanced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Cystic Fibrosis, Alpha-1 Antitrypsin Deficiency (AATD), Bronchiectasis, and Asthma in Children. Dr. Campos is currently accepting new patients.

Experienced in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Andres F. Pelaez-Freidel
Pulmonary Medicine | Intensive Care Medicine
Experienced in Alpha-1 Antitrypsin Deficiency (AATD)
Dr. Andres F. Pelaez-Freidel
Pulmonary Medicine | Intensive Care Medicine

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (22.3 mi)
305-689-8648
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Andres Pelaez-Freidel is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Miami, Florida. Dr. Pelaez-Freidel and is rated as an Advanced provider by MediFind in the treatment of Alpha-1 Antitrypsin Deficiency (AATD). His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pneumonia, Lung Metastases, and Lung Transplant. Dr. Pelaez-Freidel is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile